Table 1.

Demographics and clinical parameters of patients with TA at baseline before and after PSM.

Baseline characteristics	Total (n = 131)	Before matching			After matching
		LEF group (n = 53)	CYC group (n = 78)	p	LEF group (n = 24)	CYC group (n = 54)	p
Diagnosis age, year	34.5 ± 13.6	31.3 ± 12.4	37.0 ± 14.0	0.020	34.0 ± 12.2	36.9 ± 14.7	0.395
Female, n (%)	102 (78.5%)	43 (81.1%)	59 (75.6%)	0.457	19 (79.2%)	41 (75.9%)	0.754
Disease duration, month	20 (5.0–50.0)	18 (4.5–48.0)	20.5 (5.8–53.3)	0.659	11.5 (2.5–45.0)	18.0 (4.0–54.8)	0.314
Complication, n (%)	79 (58.1%)	33 (60.0%)	46 (59.0%)	0.706	15 (62.5%)	38 (70.4%)	0.492
Headache/dizziness	46 (35.4%)	23 (32.4%)	23 (29.5%)	0.102	10 (41.7%)	19 (35.2%)	0.585
Chest pain/distress	24 (18.5%)	9 (17.0%)	15 (19.2%)	0.744	5 (20.8%)	11 (20.4%)	0.963
Hypertension	26 (20.0%)	11 (20.8%)	15 (19.2%)	0.830	5 (20.8%)	15 (27.8%)	0.517
Cardiac dysfunction	5 (3.8%)	5 (9.4%)	0 (0.0%)	0.010	1 (4.2%)	0 (0.0%)	0.308
Renal dysfunction	3 (2.3%)	2 (3.8%)	1 (1.3%)	0.565	1 (4.2%)	1 (1.9%)	0.523
Cerebral infarction	4 (3.1%)	3 (5.7%)	1 (1.3%)	0.303	3 (12.5%)	1 (1.9%)	0.084
ESR, mm/h	15.0 (7.0–41.0)	28.0 (10.3–51.5)	11.0 (5.0–21.0)	0.000	16.0 (5.0–41.8)	11.0 (4.8–21.0)	0.268

TA, Takayasu’s arteritis; PSM, propensity score matching; LEF, leflunomide; CYC, cyclophosphamide; ESR, erythrocyte sedimentation rate.

p < 0.05 was considered there was significant different between the LEF group and CYC group.